Synthesis technology service of cabazitaxel
CAS No.: 183133-96-2
Cabazitaxel, a second-line drugs for prostate cancer, was developed by Sanofi-aventis Company. It is a semi-synthetic small molecular compound belongs to taxane.
After several years research, we found a very mature synthesis route to get cabazitaxel, with shorter steps and higher yield. 10-DAB as the start material,get the target product after 3 steps.